Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Angiotensin II receptor type 2 (AGTR2), also known as the AT2 receptor, is a seven-transmembrane G protein-coupled receptor that belongs to the renin-angiotensin system (RAS). Unlike the closely related AT1 receptor, which mediates vasoconstriction and cellular proliferation, AGTR2 activation generally counteracts these effects by promoting vasodilation, apoptosis, anti-inflammatory, and anti-fibrotic pathways. It is highly expressed during fetal development but is scantily expressed in adult tissues, though its expression is upregulated under pathological conditions such as tissue injury, inflammation, and cardiovascular stress.
Therapeutically, AGTR2 is targeted by both agonists and antagonists depending on the clinical indication. AGTR2 agonists, such as buloxibutid (Compound 21), are being investigated for their protective, anti-fibrotic, and anti-inflammatory effects in cardiovascular, renal, and pulmonary diseases, including idiopathic pulmonary fibrosis and COVID-19-related lung injury. Conversely, AGTR2 antagonists, such as EMA401 (olodanrigan), have been developed to treat peripheral neuropathic pain and are being explored for their anti-proliferative effects in cancers like glioblastoma. However, drug development has faced challenges, notably the hepatotoxicity that led to the termination of EMA401 clinical trials, and potential teratogenic risks given the receptor's critical role in fetal development.
Selective agonism of AGTR2 activates protective, anti-inflammatory, and anti-fibrotic pathways, whereas selective antagonism of AGTR2 inhibits neuropathic pain signaling and tumor cell proliferation.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Angiotensin II receptor type 2 (AGTR2).